title: [Molecular biology of renal cancer: bases for genetic directed therapy in advanced disease].
abstract: There has been expansion of therapeutic options in the management of metastatic renal cell carcinoma due to a better knowledge of the molecular biology of kidney cancers. There are different tumors grouped under the term renal cell carcinoma, being clear cell cancer the most frequent and accounting for 80% of kidney tumors. Mutations in the Von Hippel-Lindau gene can be identified in up to 80% of sporadic clear cell cancer, linking a genetically inheritable disease where vascular tumors are frequent, with renal cell cancer. Other histologic types present specific alterations in molecular pathways, like c-MET in papillary type I tumors, and Fumarase Hydratase in papillary type II tumors. Identification of the molecular alteration for a specific tumor may offer an opportunity for treatment selection based on biomarkers, and, in the future, for developing an engineering designed genetic treatment.
authors.affiliation: Servicio de Oncología Médica, Hospital Sant Pau, Barcelona, España. jmaroto@santpau.cat
authors.forename: José Pablo
authors.initials: JP
authors.lastname: Maroto Rey
authors.forename: Elena
authors.initials: E
authors.lastname: Cillán Narvaez
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008967:Molecular Biology; D009362:Neoplasm Metastasis